Antonio Guglietta

Argenx (Belgium) — Belgium

Neuroscience · Life Sciences

26h-index3.0kcitations88works18.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuropeptides and Animal Physiology(17), Chemical Synthesis and Analysis(10), Receptor Mechanisms and Signaling(10), Myasthenia Gravis and Thymoma(10), Helicobacter pylori-related gastroenterology studies(8)

Publications88 total

Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Drugs in R&D·2024· 1 citedOpen Access
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
UNC Libraries·2024Open Access
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Frontiers in Neurology·2024· 53 citedOpen Access
Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study
Neurology·2022· 10 cited
PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
HemaSphere·2022· 2 citedOpen Access
Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study (S25.004)
Neurology·2022· 2 cited
Infrared Thermography Images Acquisition for a Technical Perspective in Screening and Diagnostic Processes: Protocol Standardized Acquisition
Cureus·2021· 8 citedOpen Access
Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results
Journal of the Neurological Sciences·2021· 1 cited
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet Neurology·2021· 589 citedOpen Access
Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)
Neurology·2021· 19 cited
PND105 THE ECONOMIC AND QUALITY OF LIFE BURDEN THAT MYASTHENIA GRAVIS HAS ON PATIENTS: A US TARGETED LITERATURE REVIEW
Value in Health·2020· 1 cited
Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis (4484)
Neurology·2020· 1 cited
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
Neurology·2019· 270 citedOpen Access
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Journal of Clinical Investigation·2018· 335 citedOpen Access
Recurrent Urinary Tract Infections in Women: Risk Factors, Etiology, Pathogenesis and Prophylaxis
Future Microbiology·2017· 87 cited
Drug Treatment of Sleep Disorders
Milestones in drug therapy·2014· 11 cited
The Past, Present, and Future of Drug Development and Treatment in Sleep Disorders
Milestones in drug therapy·2014
Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders
Milestones in drug therapy·2014· 1 cited
Lorediplon: A New GABAA Modulator Drug for Treatment of Insomnia
Milestones in drug therapy·2014· 6 cited
A single‐dose, randomized, double‐blind, double dummy, placebo and positive‐controlled, five‐way cross‐over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects
Human Psychopharmacology Clinical and Experimental·2014· 17 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Charles A. Lesch(8), Vera Bril(5), Peter Ulrichts(5), Jan J.G.M. Verschuuren(5), Renato Mantegazza(5), Roberto Castiglione(5), James F. Howard(4), Tuan Vu(4), Stojan Perić(4), Hiroyuki Murai(4), Kimiaki Utsugisawa(4), Marija Veljača(4), J. Terencio(4), Albert Palomer(4), B.J. Irons(4), Savion Gropper(4), Chafic Karam(3), Andreas Meisel(3), Said R. Beydoun(3), Yuntao Song(3)